title: Possible adverse effects of SGLT2 inhibitors on bone.
authors.affiliation: Diabetes, Endocrinology, and Obesity Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA; Division of Diabetes, Endocrinology, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: simeon.taylor@nih.gov.
authors.forename: Simeon I
authors.initials: SI
authors.lastname: Taylor
authors.affiliation: Diabetes, Endocrinology, and Obesity Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Jenny E
authors.initials: JE
authors.lastname: Blau
authors.affiliation: Diabetes, Endocrinology, and Obesity Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Kristina I
authors.initials: KI
authors.lastname: Rother
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects; D050723:Fractures, Bone / Q000139:chemically induced* / Q000453:epidemiology / Q000378:metabolism; D005960:Glucosides / Q000009:adverse effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin